Quadrant Capital Group’s Apellis Pharmaceuticals APLS Stock Holding History

Quadrant Capital Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.66K	Sell	91 -734	-89%	-$15.8K	﹤0.01%	2415
2025 Q4	$20.7K	Buy	825 +656	+388%	+$15.4K	﹤0.01%	1977
2025 Q3	$3.83K	Buy	+169	New	+$3.94K	﹤0.01%	2367
2025 Q1	–	Sell	-261	Closed	-$8.33K	–	2749
2024 Q4	$8.33K	Buy	261 +222	+569%	+$6.68K	﹤0.01%	2182
2024 Q3	$1.13K	Sell	39 -103	-73%	-$3.81K	﹤0.01%	2577
2024 Q2	$5.45K	Sell	142 -38	-21%	-$1.72K	﹤0.01%	2273
2024 Q1	$10.6K	Buy	180 +6	+3%	+$382	﹤0.01%	2083
2023 Q4	$10.4K	Sell	174 -33	-16%	-$1.67K	﹤0.01%	2053
2023 Q3	$7.88K	Buy	207 +84	+68%	+$3.69K	﹤0.01%	2050
2023 Q2	$11.2K	Hold	123	–	–	﹤0.01%	1952
2023 Q1	$8.11K	Buy	+123	New	+$7.1K	﹤0.01%	2110
2022 Q3	–	Sell	-84	Closed	-$4K	–	2630
2022 Q2	$4K	Buy	+84	New	+$3.83K	﹤0.01%	2013
2021 Q4	–	Sell	-8	Closed	–	–	2496
2021 Q3	$0	Buy	+8	New	+$449	﹤0.01%	2492

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Quadrant Capital Group's APLS Position: Q1 2026 in Review

Quadrant Capital Group reduced its Apellis Pharmaceuticals (APLS) stake by 89% in Q1 2026, selling an estimated $15.8K and leaving 91 shares worth $3.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.

Quadrant Capital Group first reported a position in APLS in Q3 2021 and has held it in 13 quarters since. The position peaked at $20.7K in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Quadrant Capital Group held 91 shares of Apellis Pharmaceuticals worth $3.66K as of Q1 2026.
Quadrant Capital Group sold 734 Apellis Pharmaceuticals shares in Q1 2026, an estimated $15.8K.
Apellis Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2415 holding.
Quadrant Capital Group first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
Quadrant Capital Group's Apellis Pharmaceuticals position peaked at $20.7K in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.